Hillhurst Biopharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2012-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.hillhurstbio.com
A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Hillhurst Biopharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT06144749
- Locations
- 🇺🇸
Contact Company, San Diego, California, United States
A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers
- First Posted Date
- 2019-04-25
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Hillhurst Biopharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03926819
- Locations
- 🇺🇸
Contact Company, San Diego, California, United States
© Copyright 2025. All Rights Reserved by MedPath